The depletion of cellular ATP by AG2034 mediates cell death or cytostasis in a hypoxanthine-dependent manner in human prostate cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 2, 2008, Pages 215-226

  Obajimi, Oluwakemi ^a,b   Melera, Peter W ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

AG2034; AMP Kinase; ATP depletion; Clonogenic assay; Glycine incorporation; Hypoxanthine conversion; Prostate cancer

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; GLYCINE; HYPOXANTHINE; N [[5 [2 (2 AMINO 4,6,7,8 TETRAHYDRO 4 OXO 1H PYRIMIDO[5,4 B][1,4]THIAZIN 6 YL)ETHYL] 2 THIENYL]CARBONYL]GLUTAMIC ACID; THYMIDINE;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DRUG EFFECT; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIQUID SCINTILLATION COUNTING; PRIORITY JOURNAL; PROSTATE CANCER; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMATES; HUMANS; HYPOXANTHINE; MALE; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROSTATIC NEOPLASMS; PYRIMIDINES;

EID: 43749109891     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0593-6     Document Type: Article

References (31)

1. Allegra CJ, Chabner BA, Drakes JC, Lutz R, Rodbard D, Jolivet J (1985) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720-9726
2. Allegra CJ, Drake JC, Jolivet J, Chabner BA (1985) Inhibition of phosphoribosylaminoimidazole carboxamide transformylase by methotrexate and dihydrofolate polyglutamylates. Proc Natl Acad Sci USA 82:4881-4885
3. Bartlett CA, Boritzki TJ, Dagostino EF, Margosiak SA, Palmer CL, Romines WH, Varney MD (1999) Biological properties of AG2037: a new inhibitor of glycinamide ribonucleotide formyltransferase with low affinity for the folate receptor. Proc Am Assoc Cancer Res 40:291
4. Beardsley GP Moroson BA, Taylor EC, Moran RG (1989) A new folate antimetabolite, 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol Chem 264:328-333
5. Bissett D, McLeod HL, Sheedy B, Collier M, Pithavala Y, Paradiso L, Pitsiladis M, Cassidy J (2001) Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034. Br J Cancer 84:308-312
6. Boritzki TJ, Barlett CA, Zhang C, Howland EE, Margosiak SA, Palmer CL, Romines WH, Jackson RC (1996) AG2034: a novel inhibitor of glycinamide ribonucleotide formyltransferase. Invest New Drugs 14:295-303
7. Bosson G (2003) Reduced folate carrier: biochemistry and molecular biology of the normal and methotrexate-resistant cell. Br J Biomed Sci 60:117-129
8. Bronder JL, Moran RG (2002) Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res 62:5236-5241
9. Bronder JL Moran RG (2003) A defect in the p53 response pathway induced by de novo purine synthesis inhibition. J Biol Chem 278:48861-48871
10. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Kolzumi S, Drake JC, Jolivet J (1985) Polyglutamylation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907-912
11. Chen Z, Lu W, Garcia-Prieto C, Huang P (2007) The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr [Epub ahead of print doi: 10.1007/s10863-007-9086-x]
12. Chintalacharuvu S, Evans GF, Shih C, Bryant HU, Sandusky GE, Zuckerman SH (2005) Inhibition of glycinamide ribonucleotide formyltransferase results in selective inhibition of macrophage cytokine secretion in vitro and in vivo efficacy in rat adjuvant arthritis. Clin Exp Rheumatol 23:438-446
13. Corton JM, Gillespie JG, Hawley SA, Hardie DG (1995) 5-aminoimidazole-4- carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells. Eur J Biochem 229(2):558-565
14. Franklin RB, Costello LC (1997) Intermediary energy metabolism of normal and malignant prostate epithelial cells. In: Naz RK (ed) Prostate: basic and clinical aspects. CRC, New York, p 115
15. Gangjee A, Elzein E, Kothare M, Vasudevan A (1996) Classical and nonclassical antifolates as potential antitumor, antipneumocystis and antitoxoplasma agents. Curr Pharm Des 2:263-280
16. Hardie DG, Hawley SA, Scott JW (2006) AMP-activated protein kinase- development of the energy sensor concept. J Physiol 574:7-15
17. Jackson RC, Harkrader RJ (1981) The contributions of de novo and salvage pathways of nucleotide biosynthesis in normal and malignant cells. In: Tattersall MHN, Fox RM (eds) Nucleosides and cancer treatment. Academic, Sydney, p 18
18. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA (1999) Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 24:22-25
19. Lu X, Errington J, Chen VJ, Curtin NJ, Boddy AV, Newell DR (2000) Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines. Clin Cancer Res 6:271-277
20. Melera PW (2002) Resistance to inhibitors of dihydrofolate reductase, 2nd edn. In: Bertino JR (ed) Encyclopedia of cancer, vol IV. Academic, New York, p 115
21. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E (2007) Energy metabolism in tumor cells. FEBS J 274:1393-1418
22. Ray MS, Muggia FM, Leichman CG, Grunberg SM, Nelson RL, Dyke RW, Moran RG (1993) Phase 1 study of (6R)-5, 10-dideazatetrahydrofolate: a folate antimetabolite inhibitory to de novo purine synthesis. J Natl Cancer Inst 85:1154-1159
23. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM (2002) Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62:4427-4433
24. Scagliotti GV, Selvaggi G (2006) Antimetabolites and cancer: emerging data with a focus on antifolates. Expert Opin Ther Pat 16:189-200
25. Sellevold OFM, Jynge P, Aarstad K (1986) High performance liquid chromatography: a rapid isocratic method for determination of creatine compounds and adenine nucleotides in myocardial tissue. J Mol Cell Cardiol 18:517-527
26. Smith SG, Lehman NL, Moran RG (1993) Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res 53:5697-5706
27. Warburg O (1956) On the origin of cancer cells. Science 123:309-314
28. Weber G, Nagai M, Natsumeda Y, Ichikawa S, Nakamura H, Eble JN, Jayaram HN, Zhen WN, Paulik E, Hoffman R et al (1991) Regulation of de novo and salvage pathways in chemotherapy. Adv Enzyme Regul 31:45-67
29. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321:161-167
30. Zhang CC, Boritzki TJ, Jackson RC (1998) An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint. Cancer Chemother Pharmacol 41:223-228
31. Zhu W-Y, Melera PW (2001) Basal levels of metallothionein I and II expression in mouse embryo fibroblasts enhance growth in low folate through a cell cycle mediated pathway. Cell Biology Int 25:1261-1269